NVO vs. REGN
Compare and contrast key facts about Novo Nordisk A/S (NVO) and Regeneron Pharmaceuticals, Inc. (REGN).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or REGN.
Correlation
The correlation between NVO and REGN is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVO vs. REGN - Performance Comparison
Key characteristics
NVO:
-1.27
REGN:
-1.38
NVO:
-1.91
REGN:
-1.95
NVO:
0.75
REGN:
0.76
NVO:
-0.88
REGN:
-0.73
NVO:
-1.87
REGN:
-1.34
NVO:
26.63%
REGN:
26.93%
NVO:
39.32%
REGN:
26.14%
NVO:
-71.29%
REGN:
-91.81%
NVO:
-56.57%
REGN:
-49.12%
Fundamentals
NVO:
$296.36B
REGN:
$66.76B
NVO:
$3.27
REGN:
$38.35
NVO:
20.52
REGN:
15.92
NVO:
1.04
REGN:
0.91
NVO:
$225.05B
REGN:
$11.06B
NVO:
$190.45B
REGN:
$9.40B
NVO:
$113.24B
REGN:
$3.94B
Returns By Period
In the year-to-date period, NVO achieves a -26.11% return, which is significantly lower than REGN's -14.17% return. Over the past 10 years, NVO has outperformed REGN with an annualized return of 10.75%, while REGN has yielded a comparatively lower 3.35% annualized return.
NVO
-26.11%
-30.05%
-44.79%
-48.54%
17.85%
10.75%
REGN
-14.17%
-9.60%
-39.74%
-35.70%
4.40%
3.35%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. REGN — Risk-Adjusted Performance Rank
NVO
REGN
NVO vs. REGN - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NVO vs. REGN - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 2.58%, more than REGN's 0.14% yield.
TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 2.58% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
REGN Regeneron Pharmaceuticals, Inc. | 0.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
NVO vs. REGN - Drawdown Comparison
The maximum NVO drawdown since its inception was -71.29%, smaller than the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for NVO and REGN. For additional features, visit the drawdowns tool.
Volatility
NVO vs. REGN - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 13.88% compared to Regeneron Pharmaceuticals, Inc. (REGN) at 10.26%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NVO vs. REGN - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities